Related Experiment Videos
Qualitative overview of randomized trials of aminoglycosides
Abstract:
A qualitative overview was conducted of randomized clinical trials comparing two or more of the following aminoglycoside antibiotics--amikacin. gentamicin, netilmicin, sisomicin, and tobramycin--with respect to efficacy, nephrotoxicity, or auditory toxicity. Design features considered included number of participants in each treatment arm, proportion of randomized participants available for analysis, blinding of evaluators, and report of statistically significant results. The proportion of participants eligible for analysis was less than or equal to 75 percent for 66 percent of the comparisons regarding nephrotoxicity, 43 percent regarding efficacy, and 19 percent regarding auditory toxicity. Twenty-nine percent of the trials reported that evaluators were blinded to treatment group assignments. The results of most trials showed no significant differences, although sample sizes were, in general, smaller than necessary to detect moderate differences. Quantitative overviews may be a useful means of detecting real differences in risk that are not apparent from the results of several individual small trials.
Insights
This review of randomized trials found that most studies comparing aminoglycoside antibiotics like amikacin and gentamicin had small sample sizes. Many trials lacked sufficient participants for analysis, potentially masking real differences in efficacy and toxicity.
Area of Science:
- Pharmacology
- Clinical Trials
- Toxicology
Background:
- Aminoglycoside antibiotics are crucial for treating severe bacterial infections.
- Assessing comparative efficacy and toxicity of these drugs is vital for clinical decision-making.
- Previous studies often yielded inconclusive results due to methodological limitations.
Purpose of the Study:
- To qualitatively review randomized clinical trials (RCTs) comparing amikacin, gentamicin, netilmicin, sisomicin, and tobramycin.
- To evaluate trial design features, including participant numbers, analysis eligibility, and blinding.
- To assess reported efficacy, nephrotoxicity, and auditory toxicity.
Main Methods:
- Qualitative overview of existing randomized clinical trials.
- Analysis of trial design elements: sample size, participant eligibility for analysis, evaluator blinding.
- Assessment of reported outcomes: efficacy, nephrotoxicity, auditory toxicity.
Main Results:
- A high proportion of trials had ≤75% of participants eligible for analysis (66% for nephrotoxicity, 43% for efficacy, 19% for auditory toxicity).
- Only 29% of trials reported evaluator blinding.
- Most trials reported no significant differences, often due to inadequate sample sizes to detect moderate effects.
Conclusions:
- Many randomized trials comparing aminoglycosides suffer from methodological weaknesses, including low participant eligibility for analysis and insufficient sample sizes.
- These limitations may obscure genuine differences in efficacy and toxicity profiles among aminoglycoside antibiotics.
- Quantitative overviews are recommended to identify subtle but significant differences in risk not apparent in individual small trials.